\begin{longtable}{p{0.2\textwidth}p{0.12\textwidth}p{0.12\textwidth}p{0.12\textwidth}p{0.12\textwidth}p{0.12\textwidth}}
   & 2021 Jan-Jun & 2021 Jul-Dec & 2022 Jan-Jun & 2022 Jul-Dec & 2023 Jan-Jun \\ 
  \hline 
\endfirsthead 
\multicolumn{6}{p{\textwidth}}{{ \bfseries \tablename \thetable{} -- continued from previous page}} \ 
\hline Feature & 2021 Jan-Jun & 2021 Jul-Dec & 2022 Jan-Jun & 2022 Jul-Dec & 2023 Jan-Jun \\ \hline 
\endhead 
\hline \multicolumn{6}{p{\textwidth}}{{Continued on next page}} \\ \hline 
\endfoot 
\hline 
\endlastfoot 
 \hline
 & (N=23852) & (N=27446) & (N=33930) & (N=44701) & (N=66569) \\ 
  Age &  &  &  &  &  \\ 
    Mean (SD) & 59 (13) & 57 (14) & 56 (14) & 55 (14) & 55 (14) \\ 
  Age Group &  &  &  &  &  \\ 
    0-17 & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) & 0 (0\%) \\ 
    18-44 & 3842 (16\%) & 5333 (19\%) & 7131 (21\%) & 10763 (24\%) & 16606 (25\%) \\ 
    45-64 & 11807 (50\%) & 13868 (51\%) & 16928 (50\%) & 22636 (51\%) & 33429 (50\%) \\ 
    65+ & 8203 (34\%) & 8245 (30\%) & 9871 (29\%) & 11302 (25\%) & 16534 (25\%) \\ 
  Sex &  &  &  &  &  \\ 
    Female & 13903 (58\%) & 17366 (63\%) & 21757 (64\%) & 30638 (69\%) & 46385 (70\%) \\ 
    Male & 9921 (42\%) & 10046 (37\%) & 12147 (36\%) & 14033 (31\%) & 20156 (30\%) \\ 
    Unknown & 28 (0\%) & 34 (0\%) & 26 (0\%) & 30 (0\%) & 28 (0\%) \\ 
  Race &  &  &  &  &  \\ 
    White & 16961 (71\%) & 19049 (69\%) & 23644 (70\%) & 31997 (72\%) & 47433 (71\%) \\ 
    Black & 3536 (15\%) & 4614 (17\%) & 5787 (17\%) & 7390 (17\%) & 10442 (16\%) \\ 
    Asian & 766 (3\%) & 799 (3\%) & 955 (3\%) & 1051 (2\%) & 1607 (2\%) \\ 
    AI or AN & 199 (1\%) & 222 (1\%) & 255 (1\%) & 346 (1\%) & 416 (1\%) \\ 
    NH or PI & 118 (0\%) & 113 (0\%) & 154 (0\%) & 220 (0\%) & 273 (0\%) \\ 
    Other Race & 1374 (6\%) & 1712 (6\%) & 1988 (6\%) & 2343 (5\%) & 3825 (6\%) \\ 
    Declined to answer & 351 (1\%) & 236 (1\%) & 285 (1\%) & 335 (1\%) & 640 (1\%) \\ 
    Unknown & 547 (2\%) & 701 (3\%) & 862 (3\%) & 1019 (2\%) & 1933 (3\%) \\ 
  Ethnicity &  &  &  &  &  \\ 
    Hispanic or Latino & 2948 (12\%) & 2946 (11\%) & 3772 (11\%) & 4828 (11\%) & 7274 (11\%) \\ 
    Not Hispanic or Latino & 19460 (82\%) & 23025 (84\%) & 28388 (84\%) & 37782 (85\%) & 55999 (84\%) \\ 
    Declined to answer & 343 (1\%) & 339 (1\%) & 364 (1\%) & 443 (1\%) & 852 (1\%) \\ 
    Unknown & 1101 (5\%) & 1136 (4\%) & 1406 (4\%) & 1648 (4\%) & 2444 (4\%) \\ 
  T2D & 18410 (77\%) & 18876 (69\%) & 22096 (65\%) & 25325 (57\%) & 32612 (49\%) \\ 
  Obesity or Overweight & 17662 (74\%) & 23343 (85\%) & 29128 (86\%) & 39428 (88\%) & 60394 (91\%) \\ 
  FDA-labeled Use &  &  &  &  &  \\ 
    T2D & 18519 (78\%) & 19058 (69\%) & 22142 (65\%) & 29602 (66\%) & 36583 (55\%) \\ 
    Obesity & 1215 (5\%) & 2782 (10\%) & 3740 (11\%) & 3708 (8\%) & 13000 (20\%) \\ 
    Unknown & 4118 (17\%) & 5606 (20\%) & 8048 (24\%) & 11391 (25\%) & 16986 (26\%) \\ 
  Generic &  &  &  &  &  \\ 
    Semaglutide & 9935 (42\%) & 15724 (57\%) & 21546 (64\%) & 25759 (58\%) & 49053 (74\%) \\ 
    Dulaglutide & 8542 (36\%) & 7793 (28\%) & 8524 (25\%) & 7980 (18\%) & 6952 (10\%) \\ 
    Liraglutide & 4473 (19\%) & 3450 (13\%) & 3365 (10\%) & 4126 (9\%) & 2802 (4\%) \\ 
    Tirzepatide & 1 (0\%) & 0 (0\%) & 104 (0\%) & 6531 (15\%) & 7483 (11\%) \\ 
    Exenatide & 671 (3\%) & 301 (1\%) & 203 (1\%) & 141 (0\%) & 113 (0\%) \\ 
    Lixisenatide & 230 (1\%) & 178 (1\%) & 188 (1\%) & 164 (0\%) & 166 (0\%) \\ 
  Brand &  &  &  &  &  \\ 
    Ozempic & 5218 (22\%) & 6776 (25\%) & 8611 (25\%) & 10168 (23\%) & 16546 (25\%) \\ 
    Rybelsus & 2058 (9\%) & 2610 (10\%) & 3236 (10\%) & 3349 (7\%) & 3698 (6\%) \\ 
    Wegovy & 15 (0\%) & 1809 (7\%) & 2653 (8\%) & 2229 (5\%) & 12074 (18\%) \\ 
    Trulicity & 8542 (36\%) & 7793 (28\%) & 8524 (25\%) & 7981 (18\%) & 6952 (10\%) \\ 
    Victoza & 1558 (7\%) & 1100 (4\%) & 891 (3\%) & 721 (2\%) & 695 (1\%) \\ 
    Saxenda & 1200 (5\%) & 973 (4\%) & 1087 (3\%) & 1479 (3\%) & 926 (1\%) \\ 
    Mounjaro & 0 (0\%) & 0 (0\%) & 104 (0\%) & 6531 (15\%) & 7483 (11\%) \\ 
    Bydureon & 516 (2\%) & 241 (1\%) & 153 (0\%) & 96 (0\%) & 84 (0\%) \\ 
    Byetta & 47 (0\%) & 18 (0\%) & 16 (0\%) & 15 (0\%) & 11 (0\%) \\ 
    Soliqua & 209 (1\%) & 168 (1\%) & 171 (1\%) & 150 (0\%) & 146 (0\%) \\ 
    Unknown & 4489 (19\%) & 5958 (22\%) & 8484 (25\%) & 11982 (27\%) & 17954 (27\%) \\ 
  Atrial Fibrilation & 1914 (8\%) & 2092 (8\%) & 2460 (7\%) & 2993 (7\%) & 4200 (6\%) \\ 
  Asthma & 4023 (17\%) & 5110 (19\%) & 6515 (19\%) & 9060 (20\%) & 13657 (21\%) \\ 
  CKD & 4202 (18\%) & 4327 (16\%) & 5248 (15\%) & 6143 (14\%) & 7853 (12\%) \\ 
  COPD & 2160 (9\%) & 2284 (8\%) & 2713 (8\%) & 3325 (7\%) & 4621 (7\%) \\ 
  Glaucoma & 646 (3\%) & 649 (2\%) & 850 (3\%) & 1016 (2\%) & 1406 (2\%) \\ 
  Heart Failure & 2406 (10\%) & 2585 (9\%) & 3121 (9\%) & 3542 (8\%) & 4819 (7\%) \\ 
  Hyperlipidemia & 15853 (66\%) & 18497 (67\%) & 22871 (67\%) & 29511 (66\%) & 42372 (64\%) \\ 
  Hypertension & 16245 (68\%) & 18842 (69\%) & 23262 (69\%) & 29815 (67\%) & 42434 (64\%) \\ 
  Ischemic Heart Disease & 2278 (10\%) & 2451 (9\%) & 3006 (9\%) & 3294 (7\%) & 4522 (7\%) \\ 
  Acute MI & 932 (4\%) & 1047 (4\%) & 1317 (4\%) & 1413 (3\%) & 1860 (3\%) \\ 
  Ischemic Stroke & 94 (0\%) & 89 (0\%) & 105 (0\%) & 120 (0\%) & 169 (0\%) \\ 
  Major Depressive Disorder & 4740 (20\%) & 5904 (22\%) & 7487 (22\%) & 10137 (23\%) & 14854 (22\%) \\ 
  Osteoporosis & 820 (3\%) & 950 (3\%) & 1205 (4\%) & 1540 (3\%) & 2343 (4\%) \\ 
  Bariatric Surgery & 518 (2\%) & 805 (3\%) & 1076 (3\%) & 1451 (3\%) & 2401 (4\%) \\ 
  Metformin & 14250 (60\%) & 14798 (54\%) & 17374 (51\%) & 19701 (44\%) & 25673 (39\%) \\ 
  SGLT2i & 5122 (21\%) & 5120 (19\%) & 6230 (18\%) & 7166 (16\%) & 9002 (14\%) \\ 
  DPP4 & 3795 (16\%) & 4014 (15\%) & 4283 (13\%) & 4122 (9\%) & 4748 (7\%) \\ 
  Sulfonylurea & 6602 (28\%) & 6530 (24\%) & 7185 (21\%) & 7116 (16\%) & 8381 (13\%) \\ 
  Insulin & 2539 (11\%) & 2811 (10\%) & 3272 (10\%) & 3583 (8\%) & 4715 (7\%) \\ 
  Orlistat & 46 (0\%) & 64 (0\%) & 69 (0\%) & 85 (0\%) & 118 (0\%) \\ 
  Phentermine Topiramate & 126 (1\%) & 168 (1\%) & 216 (1\%) & 249 (1\%) & 396 (1\%) \\ 
  BMI &  &  &  &  &  \\ 
    Mean (SD) & 37 (8.7) & 37 (8.7) & 38 (8.8) & 38 (8.6) & 38 (8.3) \\ 
    Missing & 12845 (53.9\%) & 11586 (42.2\%) & 14288 (42.1\%) & 20301 (45.4\%) & 27808 (41.8\%) \\ 
  Weight (in lbs) &  &  &  &  &  \\ 
    Mean (SD) & 240 (59) & 240 (60) & 230 (58) & 230 (56) & 230 (55) \\ 
    Missing & 11135 (46.7\%) & 11334 (41.3\%) & 11497 (33.9\%) & 10854 (24.3\%) & 17555 (26.4\%) \\ 
  HbA1c &  &  &  &  &  \\ 
    Mean (SD) & 8.2 (1.9) & 7.9 (2.0) & 7.7 (2.0) & 7.3 (1.9) & 7.0 (1.8) \\ 
    Missing & 4885 (20.5\%) & 7519 (27.4\%) & 9885 (29.1\%) & 14334 (32.1\%) & 24376 (36.6\%) \\ 
  \hline
\caption{Characteristics of patients initiating a GLP-1 RA, by period (part 2).\Abbreviations: 
ADM=anti-diabetic medication,
AI  = American Indian, 
AN = Alaska Native, 
AOM=anti-obesity medication, 
Black = Black or African American, 
BMI = body mass index,
CKD=chronic kidney disease, 
COPD=chronic obstructive pulmonary disease, 
DPP4= dipeptidyl peptidase 4 inhibitor, 
FDA=Food and Drug Administration, 
HbA1c=hemoglobin A1C, 
MI=myocardial infarction, 
NH = Native Hawaiian, 
PI = Pacific Islander, 
SD=standard deviation, 
SGLT2i=sodium/glucose cotransporter-2 inhibitor,
T2D=type 2 diabetes mellitus.} 
\label{tab:table_1_period2}
\end{longtable}
